Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Daniel Quirk_2023
VIEWPOINTS

Daniel Quirk, SVP, Head of US Medical Affairs at Bristol Meyers Squibb Shares his Views on the US FDA Approval of Sotyktu

Shots: Daniel started the discussion by speaking about the epidemiology of plaque and briefed about SOTYKTU approved for the treatment of moderate-to-severe Plaque Psoriasis He also elaborated on the results from the P-III registrational studies POETYK PSO-1 and POETYK PSO-2 The interview also talks about how BMS is advancing its product portfolio to deliver innovative…
April 17, 2023

Read more

Exclusive_Stacey Williams_2023
EXCLUSIVE

Stacey Williams, Vice President, Marketing, Dermavant Shares Insights on New Campaigns for Adults with Plaque Psoriasis

Shots: Stacey talked about the launch of its first streaming commercial as part of a direct-to-consumer advertising campaign for adults with plaque psoriasis The “Topical Uprising” campaign focuses on the patient journey and taps into the frustrations & self-conscious of living with plaque psoriasis that helps patients to demand more from their topical plaque psoriasis treatment The…
January 23, 2023

Read more

Exclusive Interview_Philip M. Brown_Dr. Anna Tallman
EXCLUSIVE

Philip Brown & Anna Tallman of Dermavant Shares Insights on the Approval of its Topical Treatment for Plaque Psoriasis

Shots: Philip spoke about plaque psoriasis, symptoms, prognosis, and treatment options available. He also discussed different ongoing patient support programs by Dermavant Anna talked about the approval of Dermavant’s lead topical treatment in plaque psoriasis, its clinical studies & results The interview summarizes Dermavant’s aim to develop innovative therapeutics in immuno-dermatology to address the high…
August 1, 2022

Read more

PharmaShots Interview Daphne Chan, Head of Dermatology Medical Affairs at Janssen Shares Insights on Clinical Study in Dermatology
VIEWPOINTS

PharmaShots Interview: Daphne Chan, Head of Dermatology Medical Affairs at Janssen Shares Insights on Clinical Study in Dermatology

Shots: Daphne talked about the P-III study evaluating the safety and efficacy of Tremfya in people of color living with moderate to severe plaque psoriasis Daphne also spoke about how this clinical study will contribute to fill the gaps in care of people who are devoid of treatment due to racial and ethnic variations The…
July 26, 2022

Read more

PharmaShots Interview Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof
VIEWPOINTS

PharmaShots Interview: Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof

In an interview with PharmaShots, Philip Brown, Chief Medical Officer at Dermavant share his views on the data of Tapinarof in the P-III (PSOARING 3) study for the treatment of Plaque Psoriasis & highlights new patient satisfaction data Shots: The P-III (PSOARING 3) extension study evaluates tapinarof (1%, qd) in adult patients with PsO for ~40wks. & a 4wks. safety follow-up period The…
March 15, 2022

Read more